Login / Signup

pH-Activatable Ruthenium(II) Fluorescein Salphen Schiff Base Photosensitizers for Theranostic Applications.

Martin GillardLudovic Troian-GautierAnabelle DecottigniesBenjamin Elias
Published in: Journal of medicinal chemistry (2024)
Ruthenium(II) polypyridyl complexes exhibit a lack of selectivity toward cancer tissues despite extensive studies as photosensitizers for photodynamic therapy (PDT). Here, we report pH-activatable Ru II photosensitizers for molecularly targeted PDT by exploiting the higher acidity of tumoral tissue. The fluorescein moiety, well known for its high pH sensitivity, was connected to a Ru II center to yield novel photosensitizers for pH-sensitive 1 O 2 photogeneration. Their ability to photosensitize molecular dioxygen was studied at various pHs and revealed a drastic enhancement from 0.07 to 0.66 of the 1 O 2 quantum yield under acidic conditions (pH 7.5 to pH 5.5). Their photocytotoxicity against U2OS osteosarcoma cells was also investigated at pH 5.5 and 7.5 through IC 50 determination. A strong enhancement of the photocytotoxicity reaching 930 nM was observed at pH 5.5, which showed the potential of such photosensitizers for pH-activatable PDT.
Keyphrases
  • photodynamic therapy
  • fluorescence imaging
  • gene expression
  • high resolution
  • risk assessment
  • papillary thyroid
  • young adults
  • climate change
  • single cell
  • liquid chromatography